February 9, 2023 11:09 AM ESTUpdated 12:11 PM
R&D
Pharma

Up­dat­ed: Ab­b­Vie leaves some on­col­o­gy pro­grams out of 2023 pipeline high­lights

Kyle LaHucik

Senior Reporter

In an in­vestor up­date Thurs­day morn­ing, Ab­b­Vie left eight pro­grams out of its pipeline high­lights it shared with in­vestors, as com­pared to what ex­ists on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times